Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer

Adriana Romiti, Giuseppe Tonini, Daniele Santini, Marisa Di Seri, Raffaele Masciangelo, Silvia Mezi, Attilio Verì, Lucia Santuari, Bruno Vincenzi, Antonio Brescia, Paolo Marchei, Luigi Frati, Silverio Tomao

Research output: Contribution to journalArticlepeer-review


Purpose: Colorectal cancer (CRC) is one of the major health problems of the Western world and the proportion of elderly patients with CRC is growing. Raltitrexed ('Tomudex'), a specific thymidylate synthase inhibitor, has shown efficacy and manageable toxicity in elderly CRC patients. In this retrospective study, the tolerability of raltitrexed in patients with CRC was examined in relation to age. Patients and Methods: Toxicity parameters, graded according to World Health Organization criteria, were assessed in two patient groups: 2 as a 15-minute intravenous infusion every 3 weeks) were aged >70 years (M:F 28:22; Eastern Cooperative Oncology Group performance status 0-1:2 38:12). Results: Overall, 437 cycles of chemotherapy were administered and grade 3-4 toxicity was reported in

Original languageEnglish
Pages (from-to)3071-3076
Number of pages6
JournalAnticancer Research
Issue number5
Publication statusPublished - Sep 2002


  • Chemotherapy
  • Colorectal cancer
  • Elderly
  • Raltitrexed

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer'. Together they form a unique fingerprint.

Cite this